UCB: Feedback from roadshow

NEUTRAL, Fair Value EUR71 (+1%)
News published on October Monday 5, 2015
Share on

We hosted UCB’s roadshow in Paris last Friday with IR, Antje Witte and CMO, Iris Low-Friedrich. Concerns over romozozumab’s safety are groundless at the moment. Biosimilars in the US should not affect Cimzia or to a lesser extent considering 3rd line use, seven indications and an ongoing study vs. Humira. Future less clouded following epra failure but early-stage pipeline not expected to be in phase III before 2017 year end and bolt-on M&A with a more flexible financial situation towards the mid-year does not seems to be a priority.


For more information, please contact marketing@bryangarnier.com 

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities